Bellicum Pharmaceuticals, Inc.
(NASDAQ : BLCM)

( )
BLCM PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -2.70%199.200.0%$1927.51m
NVAXNovavax, Inc. -1.64%109.0078.2%$779.91m
AMGNAmgen, Inc. -0.22%234.841.4%$520.89m
BIIBBiogen, Inc. -1.16%236.521.8%$516.56m
BNTXBioNTech SE -4.14%187.890.0%$481.06m
GILDGilead Sciences, Inc. -0.15%71.661.0%$471.40m
ILMNIllumina, Inc. -0.28%404.003.3%$405.73m
REGNRegeneron Pharmaceuticals, Inc. 0.00%615.242.7%$388.21m
VRTXVertex Pharmaceuticals, Inc. -0.65%232.531.9%$329.46m
SNSSSunesis Pharmaceuticals, Inc. 0.00%3.170.7%$221.59m
EXASEXACT Sciences Corp. 0.00%78.4317.9%$151.61m
ALNYAlnylam Pharmaceuticals, Inc. 0.00%148.508.2%$151.18m
ARNAArena Pharmaceuticals, Inc. -0.22%92.4513.7%$143.98m
INCYIncyte Corp. 1.28%75.842.4%$129.74m
BBIOBridgeBio Pharma, Inc. 0.00%12.750.0%$115.66m

Company Profile

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.